Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Salvia Divinorum/Schizophrenia

Salvia Divinorum for Schizophrenia

1 paper and 0 clinical trials exploring salvia divinorum as a treatment for schizophrenia.

CompoundDiterpenoid

Salvia Divinorum

A specialized plant species that produces salvinorin A, a potent and selective kappa-opioid agonist with intense, short-lived effects.

Full Salvia Divinorum profile
IndicationApproximately 24 million people worldwide are affected by schizophrenia.

Schizophrenia

Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.

Full Schizophrenia profile

Academic Research

1 paper
Open Accessmeta

A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness

This systematic review (mostly case reports) found scarce but consistent evidence that novel psychoactive substances can precipitate new or worsening psychotic symptoms, marked behavioural disturbance (agitation, aggression) and physiological changes in people with severe mental illness. Findings are limited by the reliance on case studies, and the authors call for clinicians to ask directly about NPS use and for further research into long‑term mental and physical effects.

Published
April 1, 2016
Journal
Journal of Psychiatric and Mental Health Nursing
Authors
Gray, R., Bressington, D., Hughes, E., Ivanecka, A.

Clinical Trials

0 trials

No clinical trials have been tagged with both Salvia Divinorum and Schizophrenia yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Salvia Divinorum papers Search all Schizophrenia trials Full Salvia Divinorum profile Full Schizophrenia profile